Servier Presentations at ISPNO 2026 Highlight Neuro-Oncology Leadership and Expanding Glioma Portfolio

Two analyses of updated three-year follow-up data from the pivotal Phase 2 FIREFLY-1 study of OJEMDA® (tovorafenib) in BRAF-altered pediatric low-grade glioma will be featured in separate oral presentations Results from a survey of pediatric low-grade glioma caregivers unveiling...